AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Orthofix Medical Inc.
Video analysis: OFIX
All videosNo video analysis for this stock yet. Request one from our team.
News: OFIX
Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.
Orthofix Medical Q2 Earnings Call Highlights
Orthofix Medical NASDAQ: OFIX reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, disciplined investment and profitable growth rather than pursuing revenue growth at any cost.
Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript
Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.13 per share a year ago.
Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress toward a more focused and consistent operating model. The Company also raised its full-year 2026 guidance for both net sales and adjusted EBITDA. All pro forma measures contained within this release exclude the impact of the discontinued M6™ product lines. Highlights Second quart.
Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 29, 2
Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
